BGMS

#4899
Bio Green Med Solution, Inc. - Common Stock
0.8 6 USD
-0.03%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.86
0.86
Jahresspanne
0.57
6.70
Tagesänderung
-3.37%
Monatliche Änderung
-1.15%
6 month change
-10.06%
Jahresänderung
-85.67%
Vorheriger Schlusskurs
0.8 9
Open
0.8 6
Tief
0.8 6
Hoch
0.8 6
Volumen
3
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Bio Green Med Solution, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Bio Green Med Solution, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Bio Green Med Solution, Inc. current report, Q1 FY2026
8-K

Bio Green Med Solution, Inc. current report, Q2 FY2011

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on April 19, 2011. The report discloses a change in the company's independent registered public accounting firm effective as of the filing date.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance regarding the audit firm.

Material Changes

  • Resignation of Auditor: Ernst & Young LLP (UK) ("E&Y UK") resigned as the independent registered public accounting firm effective April 19, 2011.
  • Appointment of New Auditor: The Board of Directors engaged Ernst & Young LLP (US) ("E&Y US") to audit financial statements for the year ended December 31, 2011, subject to stockholder ratification.
  • Audit History: E&Y UK's reports for 2009 and 2010 contained no adverse opinions, disclaimers, or qualifications regarding uncertainty, scope, or accounting principles.
  • Disagreements: There were no disagreements with E&Y UK regarding accounting principles, practices, or audit scope during the two most recent fiscal years.

Outlook, Risks, and Contingencies

Internal Control Deficiency: The filing discloses a previously reported material weakness in internal controls. E&Y UK advised the Company that it lacked effectively designed controls over the accounting for, presentation of, and disclosure of cumulative preferred stock dividends. This deficiency could prevent the timely detection of material misstatements in the computation of net loss per share and the financial statement presentation of preferred stock dividends.

Consultations: The Company did not consult E&Y US regarding the application of accounting principles to specific transactions or the matters that led to the resignation of E&Y UK.

Investor Verification Checklist

  • Verify the rationale for switching from E&Y UK to E&Y US beyond the stated resignation.
  • Review the Company's Annual Report on Form 10-K for the year ended December 31, 2010, for details on the internal control weakness regarding preferred stock dividends.
  • Confirm the status of the stockholder ratification for the engagement of E&Y US at the upcoming annual meeting.
  • Examine Exhibit 99.1 (Letter from E&Y UK) for any additional context regarding the resignation.